WHO ICTRP trial
A First-in-Human Study to Evaluate the Administration of ReoCure alone and in…
ACTRN12620000777998 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12620000777998 |
|---|---|
| Public title | A First-in-Human Study to Evaluate the Administration of ReoCure alone and in combination with Keytruda (Pembrolizumab) in Patients with Advanced Malignant Solid Tumours |
| Scientific title | A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of ReoCure as Monotherapy and in Combination with Keytruda (Pembrolizumab) in Patients with Advanced Malignant Solid Tumours |
| Primary sponsor | ViroCure, Inc. |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 1 |
| Countries | Australia |
| Conditions | Advanced Malignant Solid Tumours; Advanced Malignant Solid Tumours;Cancer - Any cancer |
| Interventions | This research study involves a test drug called ReoCure alone or in combination with another drug called Keytruda® (pembrolizumab). ReoCure is a live Reovirus, commonly isolated from human digestive and respiratory tracts and has not been… |
| Registration date | Jul 30, 2020 |
| Target size | 45 |
| Secondary IDs | VCT-001 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: